2Cheavalier P, Tabib A, Meyronnet D, et al. Quantitative study of nerves of the human left atrium[J]. Heart Rhythm, 2005,2(5):518 - 522.
3Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Artial fibrillation begets artial fibrillation: a study in awake chronically intsrtumented goats[J]. Circulation, 1995,92(7) : 1954 - 1%8.
4Healey JS, Baranchuk A, Crystal E, et al. prevention of atrial fibrillation with angiotensin-converting enzyme inhlbitors and angiotensin receptor blockers: a rata-analysis [ J ]. J Am Coll Cardiol, 2005, 45 ( 11 ) : 1832 - 1839.
5Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrillation recurrence in patients with lone paroxysmal atrial fibrillation[J]. Eur Heart J, 2006,27:1841 - 1846.
6Murray KT, Mace I,C, Yang Z. Nonantiarrhythmic drug therapy for atrial fibrillation[J]. Heart Rhythm, 2007,4(Suppl) :S88 - S99.
7Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the rennin-angiotensin system: a systematic review and metaanalysis[J]. Am J Ther, 2008,15:36 - 43.
8Sing BN, Sing SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation[J]. N Engl J Med, 2005,352(18) : 1861 - 1872.
2Pstay BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation, 1997,96:2455-2461.
3Kannel WB, Wolf PA Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol ,1998,82:2N-9N.
4Jouven X, Desnos M, Guerot C, et al. Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study Ⅰ. Eur Heart J, 1999,20:896-899.
5Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 2002,347:1825-1833.
6Hagens VE, Ranchor AV, Van Sonderen E,et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol,2004,43:241-247.
7Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation,2001,104:2118-2150.
8Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation,1999, 100 :376-380.
9Wachtell K, Letho M, Gerdts E, et al. Angiotensin Ⅱ receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol,2005,45:712-719.
